VIR
VIR clinical trials: Vir Biotechnology, Inc.
Every trial on ClinicalTrials.gov where Vir Biotechnology, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 35
- Trials linked
- 22
- As lead sponsor
- 13
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
VIR on the catalyst calendar · VIR registry changes
- Primary completion Mar 2029Sponsor estimatePhase 2NCT07142811A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV InfectionVir Biotechnology, Inc. · Viral HepatitisActive, not recruitingVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 2028Sponsor estimatePhase 1/Phase 2NCT05356741To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembrolizumab in Adult...Vir Biotechnology, Inc. · Locally Advanced or Metastatic HER2-Expressing CancersRecruitingVIRLeadMRKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2026ActualPhase 3NCT06903338A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV InfectionVir Biotechnology, Inc. · Viral HepatitisActive, not recruitingVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 1, 2025ActualPhase 1NCT05844228A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218Vir Biotechnology, Inc. · Renal ImpairmentCompletedVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 9, 2025ActualPhase 1NCT05484206Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434Vir Biotechnology, Inc. · Hepatic ImpairmentCompletedVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 3NCT07128550A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With BulevirtideVir Biotechnology, Inc. · Viral HepatitisActive, not recruitingVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2031Sponsor estimatePhase 2NCT05461170SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.Vir Biotechnology, Inc. · Hepatitis D, ChronicActive, not recruitingVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 16, 2026ActualPhase 2NCT04856085Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus InfectionVir Biotechnology, Inc. · Hepatitis B, ChronicCompletedVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2029Sponsor estimatePhase 1NCT06960395Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced or Metastatic Solid TumorsVir Biotechnology, Inc. · Solid Tumor MalignanciesRecruitingVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 25, 2024ActualPhase 2NCT04412863Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus InfectionVir Biotechnology, Inc. · Chronic Hepatitis BCompletedVIRLeadALNYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 15, 2024ActualPhase 1/Phase 2NCT05612581A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B InfectionVir Biotechnology, Inc. · Hepatitis B, ChronicCompletedVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 24, 2022ActualPhase 1NCT04423393Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus InfectionVir Biotechnology, Inc. · Chronic Hepatitis BCompletedVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 5, 2023ActualPhase 2NCT05567783A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza AVir Biotechnology, Inc. · Influenza ATerminatedVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2, 2021ActualPhase 1NCT04988152A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japanese and Caucasian...Vir Biotechnology, Inc. · Covid19CompletedVIRLeadGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 5, 2023ActualPhase 1NCT05280717Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC)Vir Biotechnology, Inc. · Covid19TerminatedVIRLeadGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 19, 2022ActualPhase 3NCT04913675Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19.Vir Biotechnology, Inc. · Covid19TerminatedVIRLeadGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 20, 2021ActualPhase 2NCT04779879Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate...Vir Biotechnology, Inc. · Covid19CompletedVIRLeadGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 5, 2022ActualPhase 1NCT04725877VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy VolunteersVir Biotechnology, Inc. · HIV I InfectionCompletedVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Not registeredNo phase registeredNCT05235347Sotrovimab Expanded Access Treatment Protocol (COVID-19)Vir Biotechnology, Inc. · Covid19No longer availableVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 8, 2021ActualPhase 2/Phase 3NCT04545060VIR-7831 for the Early Treatment of COVID-19 in OutpatientsVir Biotechnology, Inc. · Covid19CompletedVIRLeadGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 1, 2021ActualPhase 1NCT04033406Study of VIR-2482 in Healthy VolunteersVir Biotechnology, Inc. · Influenza ACompletedVIRLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 3, 2020ActualPhase 1/Phase 2NCT03672188Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis BVir Biotechnology, Inc. · Chronic Hepatitis BCompletedVIRLeadALNYCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2027Sponsor estimatePhase 1NCT05997615Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate CancerAstellas Pharma Global Development, Inc. · Hormone-refractory Prostate CancerRecruitingVIRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 16, 2025ActualPhase 2NCT05970289Investigate the Efficacy and Safety of BRII-835 (VIR-2218) and PEG-IFNα Combination Therapy in Chronic HBV PatientsBrii Biosciences Limited · Chronic Hepatitis B Virus InfectionCompletedVIRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 5, 2026ActualPhase 2NCT06491563Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus...Brii Biosciences Limited · For Treatment of Chronic Hepatitis B Virus InfectionCompletedVIRCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 25 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerShowing the first 25 trials. There are 10 more in this window; the full list is part of TrialScanner.
Unlock with TrialScanner